Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ:
VERO), a global medical aesthetic technology leader, announced
financial results for the three months ended March 31, 2023.
First Quarter 2023 Summary & Recent
Highlights:
- Company continues to execute
against Transformational Plan
- Total revenue of $20.5 million,
down $5.9 million, or 22%, year-over-year
- Cash system revenue represented
approximately 66% of total systems and subscriptions revenue,
compared to 53% in the prior year period
- Operating expenses of $21.9M,
including approximately $0.9 million of costs related to
restructuring activities, down $3.3M or 13% year-over-year
- Cash used in operations down 53%
year-over-year
- GAAP net loss attributable to
stockholders of $9.7 million, compared to GAAP net loss
attributable to stockholders of $8.6 million last year.
- Adjusted EBITDA loss of $5.7
million, compared to Adjusted EBITDA loss of $5.9 million last
year.
- On February 3, 2023, the Company
announced a restructuring plan to reduce the Company’s cost
structure by a total of annual pre-tax savings of $13 million to
$15 million beginning in 2024.
- On May 11, 2023, the Company
announced that its Board of Directors approved a 1-for-15 reverse
stock split of the Company’s issued and outstanding common stock
effective 5:00 p.m. Eastern Daylight Time the same day. The
Company’s common stock began trading on The Nasdaq Capital Market
on a split-adjusted basis at the open of trading on May 12,
2023.
- On May 15, 2023, the Company
announced that it has entered into a stock purchase agreement with
funds affiliated with EW Healthcare Partners for a multi-tranche
private placement of senior convertible preferred stock for maximum
gross proceeds of up to $9,000,000.
Management Commentary:
“Our first quarter revenue results exceeded the
high-end of the Company’s expectations,” said Rajiv De Silva, Chief
Executive Officer of Venus Concept. “2023 is a year of re-focusing
the business and repositioning Venus Concept to enhance the cash
flow profile of the business and to accelerate the path to
long-term, sustainable, profitability and growth. To that end, we
are encouraged by the early progress towards our restructuring
activities designed to improve our operations and cost structure,
and our continued strategic shift to prioritize cash system sales
which together drove a 53% year-over-year reduction in cash used in
operations in Q1.”
Mr. De Silva continued: “We were pleased to
announce a new equity financing agreement with our largest
shareholder EW Healthcare Partners. We appreciate their continued
confidence in the Company. We are evaluating a series of
incremental initiatives to accelerate our path to cash flow
breakeven - without impacting our 2023 objectives. We remain highly
focused on maximizing our capital resources as we work to manage
our near-to-intermediate-term debt obligations and to further
enhance the Company’s foundation for achieving our longer-term
goals.”
First Quarter of 2023 Revenue by Region and by Product
Type: |
|
Three Months Ended March 31, |
|
2023 |
|
2022 |
|
(dollars in thousands) |
Revenues by region: |
|
|
|
|
|
United States |
$ |
10,741 |
|
$ |
13,129 |
International |
|
9,790 |
|
|
13,277 |
Total revenue |
$ |
20,531 |
|
$ |
26,406 |
|
Three Months Ended March 31, |
|
2023 |
|
2022 |
|
(dollars in thousands) |
Revenues by product: |
|
|
|
|
|
Subscription—Systems |
$ |
5,761 |
|
$ |
10,423 |
Products—Systems |
|
11,065 |
|
|
11,875 |
Products—Other (1) |
|
2,947 |
|
|
3,497 |
Services |
|
758 |
|
|
611 |
Total revenue |
$ |
20,531 |
|
$ |
26,406 |
|
(1) Products-Other include ARTAS
procedure kits, Viva tips and other consumables. |
First Quarter 2023
Financial Results: |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
2022 |
|
|
Change |
|
(in thousands, except
percentages) |
$ |
|
|
% of Total |
|
|
$ |
|
|
% of Total |
|
|
$ |
|
|
% |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription—Systems |
$ |
5,761 |
|
|
28.1 |
|
|
$ |
10,423 |
|
|
|
39.5 |
|
|
$ |
(4,662 |
) |
|
|
(44.7 |
) |
Products—Systems |
|
11,065 |
|
|
53.9 |
|
|
|
11,875 |
|
|
|
45.0 |
|
|
|
(810 |
) |
|
|
(6.8 |
) |
Products—Other |
|
2,947 |
|
|
14.3 |
|
|
|
3,497 |
|
|
|
13.2 |
|
|
|
(550 |
) |
|
|
(15.7 |
) |
Services |
|
758 |
|
|
3.7 |
|
|
|
611 |
|
|
|
2.3 |
|
|
|
147 |
|
|
|
24.1 |
|
Total |
$ |
20,531 |
|
|
100.0 |
|
|
$ |
26,406 |
|
|
|
100.0 |
|
|
$ |
(5,875 |
) |
|
|
(22.2 |
) |
Total revenue for the first quarter of 2023
decreased $5.9 million, or 22%, to $20.5 million, compared to the
first quarter of 2022. The decrease in total revenue, by region,
was driven by a 26% decrease year-over-year in international
revenue and a 18% decrease year-over-year in United States revenue.
The decrease in total revenue, by product category, was driven by a
45% decrease in lease revenue, a 7% decrease in systems revenue and
a 16% decrease in products revenue, offset partially by a 24%
increase in services revenue. The percentage of total systems
revenue derived from the Company’s subscription model was
approximately 34% in the first quarter of 2023, compared to 47% in
the prior year period.
Gross profit for the first quarter of 2023
decreased $4.1 million, or 23%, to $13.7 million compared to the
first quarter of 2022. The change in gross profit was driven
primarily by the year-over-year decline in revenue in the United
States and International markets driven by the strategic decision
to deemphasize subscription sales and the exit from unprofitable
direct markets. Gross margin was 66.7% of revenue, compared to
67.3% of revenue for the first quarter of 2022. The marginal
decrease was primarily due to a $0.4 million foreign exchange
headwind as a result of most currencies depreciating relative to
the U.S. dollar. Adjusting for these factors, our gross margins are
slightly above the prior year period.
Operating expenses for the first quarter of 2023
decreased $3.3 million, or 13%, to $21.9 million, compared to the
first quarter of 2022. The change in total operating expenses was
driven by a decrease of $3.1 million, or 28%, in sales and
marketing expenses and a decrease of $0.3 million, 3%, in general
and administrative expenses. First quarter of 2023 general and
administrative expenses include approximately $0.9 million of costs
related to restructuring activities designed to improve the
Company's operations and cost structure.
Operating loss for the first quarter of 2023 was
$8.2 million, compared to operating loss of $7.4 million for the
first quarter of 2022.
Net loss attributable to stockholders for the
first quarter of 2023 was $9.7 million, or $1.85 per share,
compared to net loss of $8.6 million, or $2.02 per share for the
first quarter of 2022. Adjusted EBITDA loss for the first quarter
of 2023 was $5.7 million, compared to adjusted EBITDA loss of $5.9
million for the first quarter of 2022.
As of March 31, 2023, the Company had cash and
cash equivalents of $6.4 million and total debt obligations of
approximately $77.8 million, compared to $11.6 million and $77.7
million, respectively, as of December 31, 2022.
Fiscal Year 2023 Revenue Guidance:
The Company continues to expect total revenue
for the twelve months ending December 31, 2023 in the range of
$90.0 million to $95.0 million, representing a decrease in the
range of approximately 9.5% to 4.5%, year-over-year, compared to
total revenue of $99.5 million for the twelve months ended December
31, 2022.
Conference Call Details:
Management will host a conference call at 8:00
a.m. Eastern Time on May 15, 2023, to discuss the results of the
first quarter of fiscal year 2023 with a question-and-answer
session. Those who would like to participate may dial 877-407-2991
(201-389-0925 for international callers) and provide access code
13737854. A live webcast of the call will also be provided on the
investor relations section of the Company's website at
ir.venusconcept.com.
For those unable to participate, a replay of the
call will be available for two weeks at 877-660-6853 (201-612-7415
for international callers); access code 13737854. The webcast will
be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical
aesthetic technology leader with a broad product portfolio of
minimally invasive and non-invasive medical aesthetic and hair
restoration technologies and reach in over 60 countries and 14
direct markets. Venus Concept’s product portfolio consists of
aesthetic device platforms, including Venus Versa, Venus Legacy,
Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss,
Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus
Concept’s hair restoration systems include NeoGraft® and the ARTAS
iX® Robotic Hair Restoration system. Venus Concept has been backed
by leading healthcare industry growth equity investors including EW
Healthcare Partners (formerly Essex Woodlands), HealthQuest
Capital, Longitude Capital Management, Aperture Venture Partners,
and Masters Special Situations.
Cautionary Statement Regarding
Forward-Looking Statements
This communication contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended and Section 21E of the Securities Exchange Act
of 1934, as amended. Any statements contained herein that are not
of historical facts may be deemed to be forward-looking statements.
In some cases, you can identify these statements by words such as
such as “anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and other similar
expressions that are predictions of or indicate future events and
future trends. These forward-looking statements include, but are
not limited to, statements about our financial performance and
metrics; the growth in demand for our systems and other products
and sustainability thereof; and the efficacy of the restructuring
plan, workforce reduction and management transition. These
forward-looking statements are based on current expectations,
estimates, forecasts, and projections about our business and the
industry in which the Company operates and management's beliefs and
assumptions and are not guarantees of future performance or
developments and involve known and unknown risks, uncertainties,
and other factors that are in some cases beyond our control. As a
result, any or all of our forward-looking statements in this
communication may turn out to be inaccurate. Factors that could
materially affect our business operations and financial performance
and condition include, but are not limited to, general economic
conditions and involve risks and uncertainties that may cause
results to differ materially from those set forth in the statements
and those risks and uncertainties described under Part II Item
1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I
Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2022. You are urged to consider
these factors carefully in evaluating the forward-looking
statements and are cautioned not to place undue reliance on the
forward-looking statements. The forward-looking statements are
based on information available to us as of the date of this
communication. Unless required by law, the Company does not intend
to publicly update or revise any forward-looking statements to
reflect new information or future events or otherwise.
Venus Concept Inc.Condensed
Consolidated Balance Sheets(In thousands of U.S.
dollars, except share and per share data) |
|
March 31, |
|
|
December 31, |
|
|
2023 |
|
|
2022 |
|
ASSETS |
|
|
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
|
Cash and cash equivalents |
$ |
6,414 |
|
|
$ |
11,569 |
|
Accounts receivable, net of
allowance of $14,207 and $13,619 as of March 31, 2023, and December
31, 2022, respectively |
|
39,147 |
|
|
|
37,262 |
|
Inventories |
|
22,673 |
|
|
|
23,906 |
|
Prepaid expenses |
|
1,619 |
|
|
|
1,688 |
|
Advances to suppliers |
|
5,861 |
|
|
|
5,881 |
|
Other current assets |
|
2,029 |
|
|
|
3,702 |
|
Total current assets |
|
77,743 |
|
|
|
84,008 |
|
LONG-TERM ASSETS: |
|
|
|
|
|
|
|
Long-term receivables,
net |
|
15,325 |
|
|
|
20,044 |
|
Deferred tax assets |
|
799 |
|
|
|
947 |
|
Severance pay funds |
|
698 |
|
|
|
741 |
|
Property and equipment,
net |
|
1,743 |
|
|
|
1,857 |
|
Operating right-of-use assets,
net |
|
5,439 |
|
|
|
5,862 |
|
Intangible assets |
|
11,063 |
|
|
|
11,919 |
|
Total long-term assets |
|
35,067 |
|
|
|
41,370 |
|
TOTAL ASSETS |
$ |
112,810 |
|
|
$ |
125,378 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
|
|
Trade payables |
$ |
7,511 |
|
|
$ |
8,033 |
|
Accrued expenses and other
current liabilities |
|
14,965 |
|
|
|
16,667 |
|
Current portion of long-term
debt |
|
7,735 |
|
|
|
7,735 |
|
Income taxes payable |
|
187 |
|
|
|
117 |
|
Unearned interest income |
|
2,222 |
|
|
|
2,397 |
|
Warranty accrual |
|
945 |
|
|
|
1,074 |
|
Deferred revenues |
|
952 |
|
|
|
1,765 |
|
Operating lease
liabilities |
|
1,688 |
|
|
|
1,807 |
|
Total current liabilities |
|
36,205 |
|
|
|
39,595 |
|
LONG-TERM LIABILITIES: |
|
|
|
|
|
|
|
Long-term debt |
|
70,078 |
|
|
|
70,003 |
|
Income tax payable |
|
379 |
|
|
|
374 |
|
Accrued severance pay |
|
834 |
|
|
|
867 |
|
Unearned interest revenue |
|
772 |
|
|
|
957 |
|
Warranty accrual |
|
391 |
|
|
|
408 |
|
Operating lease
liabilities |
|
3,932 |
|
|
|
4,221 |
|
Other long-term
liabilities |
|
426 |
|
|
|
215 |
|
Total long-term liabilities |
|
76,812 |
|
|
|
77,045 |
|
TOTAL LIABILITIES |
|
113,017 |
|
|
|
116,640 |
|
Commitments and Contingencies
(Note 9) |
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY (Note
15): |
|
|
|
|
|
|
|
Common Stock, $0.0001 par
value: 300,000,000 shares authorized as of March 31, 2023 and
December 31, 2022; 5,388,074 and 5,141,688 issued and outstanding
as of March 31, 2023, and December 31, 2022, respectively |
|
30 |
|
|
|
29 |
|
Additional paid-in
capital |
|
233,394 |
|
|
|
232,169 |
|
Accumulated deficit |
|
(234,310 |
) |
|
|
(224,105 |
) |
TOTAL STOCKHOLDERS’
EQUITY |
|
(886 |
) |
|
|
8,093 |
|
Non-controlling interests |
|
679 |
|
|
|
645 |
|
|
|
(207 |
) |
|
|
8,738 |
|
TOTAL LIABILITIES AND
STOCKHOLDERS’ EQUITY |
$ |
112,810 |
|
|
$ |
125,378 |
|
|
|
The accompanying notes are an integral part of these consolidated
financial statements. |
|
Venus Concept Inc.Condensed Consolidated
Statements of Operations(In thousands of U.S.
dollars, except per share data) |
|
Three Months Ended March 31, |
|
|
2023 |
|
|
2022 |
|
Revenue |
|
|
|
|
|
|
|
Leases |
$ |
5,761 |
|
|
$ |
10,423 |
|
Products and services |
|
14,770 |
|
|
|
15,983 |
|
|
|
20,531 |
|
|
|
26,406 |
|
Cost of goods sold |
|
|
|
|
|
|
|
Leases |
|
1,747 |
|
|
|
2,700 |
|
Products and services |
|
5,085 |
|
|
|
5,943 |
|
|
|
6,832 |
|
|
|
8,643 |
|
Gross profit |
|
13,699 |
|
|
|
17,763 |
|
Operating expenses: |
|
|
|
|
|
|
|
Selling and marketing |
|
8,032 |
|
|
|
11,084 |
|
General and administrative |
|
11,185 |
|
|
|
11,472 |
|
Research and development |
|
2,637 |
|
|
|
2,643 |
|
Total operating expenses |
|
21,854 |
|
|
|
25,199 |
|
Loss from operations |
|
(8,155 |
) |
|
|
(7,436 |
) |
Other expenses: |
|
|
|
|
|
|
|
Foreign exchange loss (gain) |
|
(352 |
) |
|
|
5 |
|
Finance expenses |
|
1,508 |
|
|
|
923 |
|
Loss on disposal of subsidiaries |
|
77 |
|
|
|
- |
|
Loss before income taxes |
|
(9,388 |
) |
|
|
(8,364 |
) |
Income tax expense |
|
235 |
|
|
|
272 |
|
Net loss |
|
(9,623 |
) |
|
|
(8,636 |
) |
Net loss attributable to
stockholders of the Company |
|
(9,657 |
) |
|
|
(8,619 |
) |
Net income (loss) attributable
to non-controlling interest |
|
34 |
|
|
|
(17 |
) |
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
Basic |
$ |
(1.85 |
) |
|
$ |
(2.02 |
) |
Diluted |
$ |
(1.85 |
) |
|
$ |
(2.02 |
) |
Weighted-average number of
shares used in per share calculation: |
|
|
|
|
|
|
|
Basic |
|
5,218 |
|
|
|
4,265 |
|
Diluted |
|
5,218 |
|
|
|
4,265 |
|
Venus Concept Inc.Condensed Consolidated
Statements of Cash
Flows(in
thousands) |
|
Three Months Ended March 31, |
|
|
2023 |
|
|
2022 |
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
Net loss |
$ |
(9,623 |
) |
|
$ |
(8,636 |
) |
Adjustments to reconcile net
loss to net cash used in operating activities: |
|
|
|
|
|
|
|
Depreciation and amortization |
|
1,007 |
|
|
|
1,101 |
|
Stock-based compensation |
|
481 |
|
|
|
443 |
|
Provision for expected credit losses |
|
618 |
|
|
|
1,004 |
|
Provision for inventory obsolescence |
|
343 |
|
|
|
135 |
|
Finance expenses and accretion |
|
74 |
|
|
|
79 |
|
Deferred tax recovery |
|
149 |
|
|
|
45 |
|
Loss on disposal of property and equipment |
|
34 |
|
|
|
- |
|
Changes in operating assets
and liabilities: |
|
|
|
|
|
|
|
Accounts receivable short-term and long-term |
|
1,654 |
|
|
|
(3,199 |
) |
Inventories |
|
891 |
|
|
|
(911 |
) |
Prepaid expenses |
|
69 |
|
|
|
291 |
|
Advances to suppliers |
|
20 |
|
|
|
(4,226 |
) |
Other current assets |
|
1,673 |
|
|
|
(381 |
) |
Operating right-of-use assets, net |
|
423 |
|
|
|
(6,299 |
) |
Other long-term assets |
|
(45 |
) |
|
|
- |
|
Trade payables |
|
(522 |
) |
|
|
2,731 |
|
Accrued expenses and other current liabilities |
|
(2,570 |
) |
|
|
(1,128 |
) |
Current operating lease liabilities |
|
(119 |
) |
|
|
1,664 |
|
Severance pay funds |
|
43 |
|
|
|
(67 |
) |
Unearned interest income |
|
(360 |
) |
|
|
70 |
|
Long-term operating lease liabilities |
|
(289 |
) |
|
|
4,635 |
|
Other long-term liabilities |
|
161 |
|
|
|
225 |
|
Net cash used in operating activities |
|
(5,888 |
) |
|
|
(12,424 |
) |
CASH FLOWS FROM
INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
Purchases of property and equipment |
|
(70 |
) |
|
|
(157 |
) |
Net cash used in investing activities |
|
(70 |
) |
|
|
(157 |
) |
CASH FLOWS FROM
FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
Proceeds from exercise of
options |
|
— |
|
|
|
23 |
|
Proceeds from issuance of
common stock |
|
803 |
|
|
|
— |
|
Repayment of government
assistance loans |
|
— |
|
|
|
(407 |
) |
Net cash (used in) provided by financing activities |
|
803 |
|
|
|
(384 |
) |
NET DECREASE IN CASH AND CASH
EQUIVALENTS AND RESTRICTED CASH |
|
(5,155 |
) |
|
|
(12,965 |
) |
CASH AND CASH EQUIVALENTS AND
RESTRICTED CASH — Beginning of period |
|
11,569 |
|
|
|
30,876 |
|
CASH AND CASH EQUIVALENTS AND
RESTRICTED CASH — End of period |
$ |
6,414 |
|
|
$ |
17,911 |
|
SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION: |
|
|
|
|
|
|
|
Cash paid for income taxes |
$ |
12 |
|
|
$ |
99 |
|
Cash paid for interest |
$ |
1,433 |
|
|
$ |
844 |
|
FINANCING
INFORMATION: |
|
|
|
|
|
|
|
Common stock issuance costs |
|
— |
|
|
|
— |
|
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as
net income (loss) before foreign exchange loss (gain), financial
expenses, income tax expense (benefit), depreciation and
amortization, stock-based compensation and non-recurring items for
a given period. Adjusted EBITDA is not a measure of our financial
performance under U.S. GAAP and should not be considered an
alternative to net income or any other performance measures derived
in accordance with U.S. GAAP. Accordingly, you should consider
Adjusted EBITDA along with other financial performance measures,
including net income, and our financial results presented in
accordance with U.S. GAAP. Other companies, including companies in
our industry, may calculate Adjusted EBITDA differently or not at
all, which reduces its usefulness as a comparative measure. We
understand that although Adjusted EBITDA is frequently used by
securities analysts, lenders and others in their evaluation of
companies, Adjusted EBITDA has limitations as an analytical tool,
and you should not consider it in isolation, or as a substitute for
analysis of our results as reported under U.S. GAAP. Some of these
limitations are: Adjusted EBITDA does not reflect our cash
expenditures or future requirements for capital expenditures or
contractual commitments; Adjusted EBITDA does not reflect changes
in, or cash requirements for, our working capital needs; and
although depreciation and amortization are non-cash charges, the
assets being depreciated will often have to be replaced in the
future, and Adjusted EBITDA does not reflect any cash requirements
for such replacements.
We believe that Adjusted EBITDA is a useful
measure for analyzing the performance of our core business because
it facilitates operating performance comparisons from period to
period and company to company by backing out potential differences
caused by changes in foreign exchange rates that impact financial
assets and liabilities denominated in currencies other than the
U.S. dollar, tax positions (such as the impact on periods or
companies of changes in effective tax rates), the age and book
depreciation of fixed assets (affecting relative depreciation
expense), amortization of intangible assets, stock-based
compensation expense (because it is a non-cash expense) and
non-recurring items as explained below.The following reconciliation
of net (loss) income to Adjusted EBITDA for the periods
presented:
Venus Concept Inc.Reconciliation of Net
loss to Non-GAAP Adjusted EBITDA |
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
2022 |
|
Reconciliation of net
loss to adjusted EBITDA |
(in thousands) |
|
Net loss |
$ |
(9,623 |
) |
|
$ |
(8,636 |
) |
Foreign exchange loss
(gain) |
|
(352 |
) |
|
|
5 |
|
Loss on disposal of
subsidiaries |
|
77 |
|
|
|
— |
|
Finance expenses |
|
1,508 |
|
|
|
923 |
|
Income tax expense |
|
235 |
|
|
|
272 |
|
Depreciation and
amortization |
|
1,022 |
|
|
|
1,101 |
|
Stock-based compensation
expense |
|
481 |
|
|
|
443 |
|
Other adjustments (1) |
|
917 |
|
|
|
— |
|
Adjusted EBITDA |
$ |
(5,735 |
) |
|
$ |
(5,892 |
) |
(1) For the three months ended March 31, 2023,
the other adjustments are represented by restructuring activities
designed to improve the Company's operations and cost
structure.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Aug 2023 to Sep 2023
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Sep 2022 to Sep 2023